Nevertheless, IL-4Rα-knockdown also rendered the cells more susceptible to IGF-I stimulation, indicating that impaired IL-4 signaling may be compensated by other mitogens abundantly present in the microenvironment of the tumor cells in vivo. The gene discussed is IGF1; the disease is neoplasm.